Jelena Martinovic

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) and Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U)(OTCQX: ACRHF, ACRDF) announced on Monday that it is anticipated that Canopy USA, LLC will complete its acquisition of Acreage on or around Dec. 9, 2024. The Canadian cannabis giant announced its plans to acquire Acreage for $3.4 billion in 2019. Initially, the deal was to be undertaken should the U.S. legalize marijuana on a federal level. That deal was later restructured. The deal outlined the plan to acquire all Class E subordinate voting shares of Acreage. This acquisition will follow the purchase of the Class D shares of Acreage, based on an agreement from October 24, 2022. After both acquisitions are completed, Canopy USA will own all shares of Acreage.

Predatory Practices Persist In Missouri's Cannabis Industry, Find Investigations Into Microbusiness Licenses

Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) explores integrating Bitcoin as an accepted payment method across its business platforms, the company said on Wednesday.The move aligns with the company's commitment to innovation and meeting the evolving preferences of its global customer base.

Zinger Key Points Poseidon Investment completed investments in BLKBRN and Dogwood Green dispensaries in New Jersey.

Zinger Key Points PA lawmakers Krajewski and Frankel are pushing for cannabis legalization in the 2025-2026 session.

October cannabis sales in Illinois hit $142.3M, up 4.2% from September, contributing to 2024's total of $1.5B.

Zinger Key Points Organigram acquires Motif Labs for up to CA$100 million, solidifying leadership in Canada's cannabis market.

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving a share price above $3.2203 within 12 months. The deal is financed through Organigram's cash reserves.

Canopy USA, LLC has wrapped up its acquisition of Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), Canopy Growth Corporation's (TSX: WEED) (NASDAQ: CGC) U.S.-domiciled holding company said on Monday. Canopy USA, created in 2022 to streamline the Canadian cannabis giant's entry into the US market, now owns 100% of the issued and outstanding shares of Acreage. The $3.4 billion acquisition deal was first in 2019. Initially, the deal was to be undertaken should the U.S. legalize marijuana on a federal level. That deal was later restructured.

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ). New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals in 2021.